Formulary Oversight For Obamacare Plans Will Be Deferred In Some States
Patient groups raise concerns that states may not be able to monitor formularies for discrimination, limiting patient access to drug coverage.
You may also be interested in...
Cigna agrees to cap cost-sharing for some HIV/AIDS drugs at $200 in its exchange plans in Florida as a result of a consent agreement with state regulators. AIDS activists had filed a complaint with HHS alleging Cigna and three other insurers in the state were discriminating against patients with their high copays for HIV/AIDS drugs.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’